CN111643524B - 从外周血中产生肿瘤反应性t细胞富集群的方法 - Google Patents
从外周血中产生肿瘤反应性t细胞富集群的方法 Download PDFInfo
- Publication number
- CN111643524B CN111643524B CN202010410564.8A CN202010410564A CN111643524B CN 111643524 B CN111643524 B CN 111643524B CN 202010410564 A CN202010410564 A CN 202010410564A CN 111643524 B CN111643524 B CN 111643524B
- Authority
- CN
- China
- Prior art keywords
- cells
- cancer
- tumor
- enriched
- reactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 137
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 96
- 210000005259 peripheral blood Anatomy 0.000 title claims abstract description 26
- 239000011886 peripheral blood Substances 0.000 title claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 title claims 2
- 210000004027 cell Anatomy 0.000 claims abstract description 199
- 238000000034 method Methods 0.000 claims abstract description 71
- 241000124008 Mammalia Species 0.000 claims abstract description 36
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims abstract description 7
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims abstract description 7
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims abstract 6
- 201000011510 cancer Diseases 0.000 claims description 55
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 239000003937 drug carrier Substances 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 8
- 230000000638 stimulation Effects 0.000 claims description 7
- 102000015696 Interleukins Human genes 0.000 claims description 6
- 108010063738 Interleukins Proteins 0.000 claims description 6
- 108010065805 Interleukin-12 Proteins 0.000 claims description 5
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 229940126638 Akt inhibitor Drugs 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 108090000172 Interleukin-15 Proteins 0.000 claims description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims description 4
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 4
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 239000003197 protein kinase B inhibitor Substances 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- VPVLEBIVXZSOMQ-UHFFFAOYSA-N 3-[[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol Chemical compound NC1=CC=CC(C=2NC3=NC=NC(OC=4C=C(O)C=CC=4)=C3C=2)=C1 VPVLEBIVXZSOMQ-UHFFFAOYSA-N 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 108091033773 MiR-155 Proteins 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 208000011932 ovarian sarcoma Diseases 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 47
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 46
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 45
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 45
- 210000004881 tumor cell Anatomy 0.000 description 21
- 230000014509 gene expression Effects 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 10
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 230000000735 allogeneic effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 239000010432 diamond Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000017578 LAG3 Human genes 0.000 description 3
- 238000011467 adoptive cell therapy Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 101150030213 Lag3 gene Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 238000011469 lymphodepleting chemotherapy Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000288105 Grus Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282418 Hominidae Species 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010025537 Malignant anorectal neoplasms Diseases 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000283089 Perissodactyla Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 206010046799 Uterine leiomyosarcoma Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 201000007696 anal canal cancer Diseases 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000025848 malignant tumor of nasopharynx Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 201000003956 middle ear cancer Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 201000007425 nasal cavity carcinoma Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 201000003437 pleural cancer Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Ecology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developmental Biology & Embryology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010410564.8A CN111643524B (zh) | 2013-03-01 | 2013-04-30 | 从外周血中产生肿瘤反应性t细胞富集群的方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361771251P | 2013-03-01 | 2013-03-01 | |
| US61/771,251 | 2013-03-01 | ||
| PCT/US2013/038813 WO2014133568A1 (en) | 2013-03-01 | 2013-04-30 | Methods of producing enriched populations of tumor reactive t cells from peripheral blood |
| CN201380075806.0A CN105163745B (zh) | 2013-03-01 | 2013-04-30 | 从外周血中产生肿瘤反应性t细胞富集群的方法 |
| CN202010410564.8A CN111643524B (zh) | 2013-03-01 | 2013-04-30 | 从外周血中产生肿瘤反应性t细胞富集群的方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380075806.0A Division CN105163745B (zh) | 2013-03-01 | 2013-04-30 | 从外周血中产生肿瘤反应性t细胞富集群的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111643524A CN111643524A (zh) | 2020-09-11 |
| CN111643524B true CN111643524B (zh) | 2023-09-05 |
Family
ID=48521400
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010410564.8A Active CN111643524B (zh) | 2013-03-01 | 2013-04-30 | 从外周血中产生肿瘤反应性t细胞富集群的方法 |
| CN201380075806.0A Active CN105163745B (zh) | 2013-03-01 | 2013-04-30 | 从外周血中产生肿瘤反应性t细胞富集群的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380075806.0A Active CN105163745B (zh) | 2013-03-01 | 2013-04-30 | 从外周血中产生肿瘤反应性t细胞富集群的方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9844569B2 (enExample) |
| EP (2) | EP3628322A1 (enExample) |
| JP (4) | JP6257655B2 (enExample) |
| CN (2) | CN111643524B (enExample) |
| AU (4) | AU2013379773B2 (enExample) |
| CA (1) | CA2902448C (enExample) |
| ES (1) | ES2771251T3 (enExample) |
| WO (1) | WO2014133568A1 (enExample) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009511081A (ja) | 2005-10-18 | 2009-03-19 | ナショナル ジューイッシュ メディカル アンド リサーチ センター | 条件的に不死化された長期幹細胞およびそのような細胞を作製および使用する方法 |
| AU2009246876B2 (en) | 2008-05-16 | 2015-04-02 | Htyr Acquisition Llc | Antibodies and processes for preparing the same |
| CA2735522C (en) | 2008-08-28 | 2017-04-18 | Taiga Biotechnologies, Inc. | Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc |
| SG10201700459XA (en) | 2012-07-20 | 2017-02-27 | Taiga Biotechnologies Inc | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
| CN111643524B (zh) * | 2013-03-01 | 2023-09-05 | 美国卫生和人力服务部 | 从外周血中产生肿瘤反应性t细胞富集群的方法 |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| WO2015085147A1 (en) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| EP3082853A2 (en) | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| EP3154350B1 (en) | 2014-04-10 | 2024-03-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
| CN107075479A (zh) | 2014-10-02 | 2017-08-18 | 美国卫生和人力服务部 | 分离对癌症特异性突变具有抗原特异性的t细胞的方法 |
| US20170218042A1 (en) * | 2014-10-02 | 2017-08-03 | The United State of America, as represented by the Secretary, Department of Health and Human Service | Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation |
| ES3049406T3 (en) | 2014-12-19 | 2025-12-16 | Broad Inst Inc | Methods for profiling the t-cell-receptor repertoire |
| EP3234193B1 (en) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Molecular biomarkers for cancer immunotherapy |
| AU2016258845B2 (en) | 2015-05-01 | 2022-03-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| CN108025048B (zh) | 2015-05-20 | 2022-10-25 | 博德研究所 | 共有的新抗原 |
| CN104946589A (zh) * | 2015-07-07 | 2015-09-30 | 英普乐孚生物技术(上海)有限公司 | 一种肿瘤特异性til细胞的分离培养方法 |
| WO2017069958A2 (en) | 2015-10-09 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
| WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
| EP3368689B1 (en) | 2015-10-28 | 2020-06-17 | The Broad Institute, Inc. | Composition for modulating immune responses by use of immune cell gene signature |
| AU2016355178B9 (en) | 2015-11-19 | 2019-05-30 | Massachusetts Institute Of Technology | Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity |
| GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
| EP3922716A1 (en) * | 2016-03-17 | 2021-12-15 | Berkeley Lights, Inc. | Selection and cloning of t lymphocytes in a microfluidic device |
| EP3481867B1 (en) | 2016-07-07 | 2024-09-04 | Iovance Biotherapeutics, Inc. | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof |
| WO2018049025A2 (en) | 2016-09-07 | 2018-03-15 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses |
| WO2018067991A1 (en) | 2016-10-07 | 2018-04-12 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| SMT202400133T1 (it) | 2016-10-26 | 2024-05-14 | Iovance Biotherapeutics Inc | Restimolazione di linfociti infiltranti il tumore crioconservati |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| WO2018089386A1 (en) | 2016-11-11 | 2018-05-17 | The Broad Institute, Inc. | Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action |
| KR102618948B1 (ko) | 2016-11-17 | 2023-12-27 | 이오반스 바이오테라퓨틱스, 인크. | 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법 |
| CN113786476A (zh) | 2016-12-02 | 2021-12-14 | 泰加生物工艺学公司 | 纳米颗粒调配物 |
| EP3565586B1 (en) | 2017-01-06 | 2025-10-08 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2018183908A1 (en) | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
| EP3606518A4 (en) | 2017-04-01 | 2021-04-07 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER |
| EP3610266A4 (en) | 2017-04-12 | 2021-04-21 | Massachusetts Eye and Ear Infirmary | TUMOR SIGNATURE FOR METASTASIS, COMPOSITIONS OF MATERIAL AND THEIR METHODS OF USE |
| US12226479B2 (en) | 2017-05-11 | 2025-02-18 | The General Hospital Corporation | Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof |
| US12006354B2 (en) | 2017-05-24 | 2024-06-11 | Novartis Ag | Antibody-IL2 engrafted proteins and methods of use in the treatment of cancer |
| JP2020522516A (ja) | 2017-06-05 | 2020-07-30 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 二重抵抗性黒色腫において腫瘍浸潤リンパ球を使用する方法 |
| WO2018232195A1 (en) | 2017-06-14 | 2018-12-20 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| WO2019014581A1 (en) | 2017-07-14 | 2019-01-17 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| JP6731114B2 (ja) | 2017-08-03 | 2020-07-29 | タイガ バイオテクノロジーズ，インク． | メラノーマの処置のための方法および組成物 |
| CN109423478A (zh) * | 2017-08-22 | 2019-03-05 | 郑州大学第附属医院 | 一种记忆性t细胞的制备方法 |
| WO2019070755A1 (en) | 2017-10-02 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER |
| WO2019084055A1 (en) | 2017-10-23 | 2019-05-02 | Massachusetts Institute Of Technology | CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS |
| WO2019094955A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas |
| US12018080B2 (en) | 2017-11-13 | 2024-06-25 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway |
| CN108254557B (zh) * | 2017-12-26 | 2019-05-31 | 首都医科大学附属北京地坛医院 | 用cd8阳性的t细胞上pd-1和tigit确定hbv相关原发性肝癌预后的系统 |
| US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
| KR20200119242A (ko) | 2018-01-08 | 2020-10-19 | 이오반스 바이오테라퓨틱스, 인크. | 종양 항원-특이적 t-세포에 대해 풍부화된 til 생성물의 생성 방법 |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
| TW202446952A (zh) | 2018-04-27 | 2024-12-01 | 美商艾歐凡斯生物治療公司 | 腫瘤浸潤性淋巴細胞之基因編輯和彼於免疫治療之用途 |
| US12473532B2 (en) | 2018-05-10 | 2025-11-18 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US20210371932A1 (en) | 2018-06-01 | 2021-12-02 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
| US12036240B2 (en) | 2018-06-14 | 2024-07-16 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
| WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
| US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
| CN113272421B (zh) | 2018-11-05 | 2025-02-18 | 艾欧凡斯生物治疗公司 | 用于产生肿瘤浸润性淋巴细胞的方法及其在免疫疗法中的用途 |
| US20220062394A1 (en) | 2018-12-17 | 2022-03-03 | The Broad Institute, Inc. | Methods for identifying neoantigens |
| US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
| WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
| US20220142948A1 (en) | 2019-03-18 | 2022-05-12 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
| WO2020210231A1 (en) | 2019-04-08 | 2020-10-15 | Taiga Biotechnologies, Inc. | Compositions and methods for the cry opreservation of immune cells |
| EP3969041A4 (en) | 2019-05-14 | 2023-05-10 | Taiga Biotechnologies, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION |
| US20220235340A1 (en) | 2019-05-20 | 2022-07-28 | The Broad Institute, Inc. | Novel crispr-cas systems and uses thereof |
| CN110452870A (zh) * | 2019-05-20 | 2019-11-15 | 河南省肿瘤医院 | 一种肿瘤特异性t细胞的分离培养方法及由其获得的产品 |
| US20220226464A1 (en) | 2019-05-28 | 2022-07-21 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
| WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
| US12421557B2 (en) | 2019-08-16 | 2025-09-23 | The Broad Institute, Inc. | Methods for predicting outcomes and treating colorectal cancer using a cell atlas |
| WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
| US12297426B2 (en) | 2019-10-01 | 2025-05-13 | The Broad Institute, Inc. | DNA damage response signature guided rational design of CRISPR-based systems and therapies |
| US12394502B2 (en) | 2019-10-02 | 2025-08-19 | The General Hospital Corporation | Method for predicting HLA-binding peptides using protein structural features |
| US12195725B2 (en) | 2019-10-03 | 2025-01-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity |
| US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
| US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
| CN115244173A (zh) | 2019-12-20 | 2022-10-25 | 英研生物(英国)有限公司 | 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途 |
| US12165747B2 (en) | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| JP2020143057A (ja) * | 2020-04-01 | 2020-09-10 | アメリカ合衆国 | がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法 |
| WO2021216920A1 (en) | 2020-04-22 | 2021-10-28 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| CN111850119B (zh) * | 2020-06-04 | 2022-08-26 | 吴式琇 | 定量检测bst1、stab1和tlr4基因表达水平的方法及应用 |
| RU2752973C1 (ru) * | 2020-10-12 | 2021-08-11 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" | Способ определения качественных параметров иммуносупрессивных клеток у онкологических пациентов |
| CN112266899A (zh) * | 2020-10-26 | 2021-01-26 | 北京卡替医疗技术有限公司 | 修饰的免疫细胞及其用途 |
| PE20241173A1 (es) | 2021-10-14 | 2024-05-28 | Arsenal Biosciences Inc | Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica |
| WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
| WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
| WO2025059533A1 (en) | 2023-09-13 | 2025-03-20 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2025097055A2 (en) | 2023-11-02 | 2025-05-08 | The Broad Institute, Inc. | Compositions and methods of use of t cells in immunotherapy |
| WO2025117544A1 (en) | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102119214A (zh) * | 2008-07-18 | 2011-07-06 | 森托科隆国际公司 | 适合于癌症治疗的包含体外扩增的t淋巴细胞和血管形成抑制剂的组合物 |
| CN102131828A (zh) * | 2007-06-18 | 2011-07-20 | 奥根农股份公司 | 针对人程序性死亡受体pd-1的抗体 |
| CN102935228A (zh) * | 2011-08-15 | 2013-02-20 | 傅阳心 | 用于肿瘤治疗的试剂、其用途及方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229115A (en) | 1990-07-26 | 1993-07-20 | Immunex Corporation | Adoptive immunotherapy with interleukin-7 |
| US5834441A (en) | 1993-09-13 | 1998-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral (AAV) liposomes and methods related thereto |
| US5656465A (en) | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
| US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
| EP1263928B1 (en) | 2000-02-11 | 2007-09-26 | Dana-Farber Cancer Institute, Inc. | Identification of antigenic peptides by cytotoxic t lymphocytes activated by dendritic cell hybrids |
| DE10232697A1 (de) | 2002-07-15 | 2004-02-05 | Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin | Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen |
| ES2602145T3 (es) | 2002-09-06 | 2017-02-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inmunoterapia con linfocitos específicos de antígeno seleccionados in vitro después de quimioterapia supresora de linfocitos no mieloablativa |
| US20040250305A1 (en) | 2002-09-09 | 2004-12-09 | Latif Zuhair A. | Adoptive transfer and uses thereof |
| EP1623017B1 (en) | 2003-05-08 | 2010-09-15 | Life Technologies Corporation | Generation and isolation of antigen-specific t cells |
| JPWO2007018198A1 (ja) * | 2005-08-09 | 2009-02-19 | 国立大学法人 熊本大学 | Ｈｌａ−ａ２陽性者用ｈｓｐ１０５由来癌拒絶抗原ペプチド及びこれを含む医薬 |
| US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
| WO2009052623A1 (en) * | 2007-10-26 | 2009-04-30 | Governing Council Of The University Of Toronto | Therapeutic and diagnostic methods using tim-3 |
| CA2713462C (en) | 2008-01-29 | 2020-04-14 | Fred Hutchinson Cancer Research Center | Identification of cd8+ t cells that are cd161hi and/or il18r(alpha)hi and have rapid drug efflux capacity |
| WO2009095278A2 (en) | 2008-01-31 | 2009-08-06 | Bayer Cropscience Ag | The use of alternan as ingredient for certain foodstuffs |
| CN101625361A (zh) | 2009-02-26 | 2010-01-13 | 中国人民解放军第二军医大学 | 一种慢性乙型肝炎患者免疫状态的诊断方法 |
| WO2012054792A2 (en) * | 2010-10-22 | 2012-04-26 | Virginia Commonwealth University | Composition and method for immunological treatment of cancer, prevention of cancer recurrence and metastasis, and overcoming immune suppressor cells |
| US20120244133A1 (en) * | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| JP2014020930A (ja) | 2012-07-18 | 2014-02-03 | Kanazawa Univ | 膵癌診断及び治療効果予測判定バイオマーカー |
| CN111643524B (zh) * | 2013-03-01 | 2023-09-05 | 美国卫生和人力服务部 | 从外周血中产生肿瘤反应性t细胞富集群的方法 |
| CN104371974B (zh) | 2014-10-24 | 2017-03-22 | 杭州阿诺生物医药科技股份有限公司 | 一种自体外周血淋巴细胞cik的培养方法 |
| CN105754990A (zh) | 2016-01-29 | 2016-07-13 | 深圳精准医疗科技有限公司 | 一种pd-1/ctla-4双特异性抗体的制备方法及其应用 |
| JP2019520038A (ja) | 2016-04-21 | 2019-07-18 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 黒色腫およびその他のがんに対する免疫療法 |
| CN106177931B (zh) | 2016-08-25 | 2018-02-02 | 河北浓孚雨生物科技有限公司 | 免疫检测点双阻断ctl高效率杀伤细胞制剂的制备方法 |
| CN106957905B (zh) | 2016-12-23 | 2020-12-04 | 孙涛 | 一种用于评估肿瘤免疫治疗效果的分子检测方法及引物组合物及试剂盒 |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| RU2662916C1 (ru) | 2017-06-05 | 2018-07-31 | Общество с ограниченной ответственностью "Альтернативные Инновационные Технологии" | Способ терапии метастатического рака с использованием вируса Сендай |
| US12259379B2 (en) | 2017-06-30 | 2025-03-25 | Osaka University | Method for predicting effect of tumor immunotherapy using tumor cytotoxic activity of peripheral blood T cells as index |
| CN108254557B (zh) | 2017-12-26 | 2019-05-31 | 首都医科大学附属北京地坛医院 | 用cd8阳性的t细胞上pd-1和tigit确定hbv相关原发性肝癌预后的系统 |
-
2013
- 2013-04-30 CN CN202010410564.8A patent/CN111643524B/zh active Active
- 2013-04-30 JP JP2015560160A patent/JP6257655B2/ja active Active
- 2013-04-30 CA CA2902448A patent/CA2902448C/en active Active
- 2013-04-30 EP EP19208596.7A patent/EP3628322A1/en active Pending
- 2013-04-30 CN CN201380075806.0A patent/CN105163745B/zh active Active
- 2013-04-30 ES ES13725231T patent/ES2771251T3/es active Active
- 2013-04-30 AU AU2013379773A patent/AU2013379773B2/en active Active
- 2013-04-30 EP EP13725231.8A patent/EP2961416B1/en active Active
- 2013-04-30 US US14/771,593 patent/US9844569B2/en active Active
- 2013-04-30 WO PCT/US2013/038813 patent/WO2014133568A1/en not_active Ceased
-
2017
- 2017-11-15 US US15/813,398 patent/US10716809B2/en active Active
- 2017-12-05 JP JP2017233698A patent/JP6903558B2/ja active Active
-
2018
- 2018-06-20 AU AU2018204458A patent/AU2018204458B2/en active Active
-
2019
- 2019-12-06 JP JP2019221431A patent/JP7029617B2/ja active Active
- 2019-12-24 AU AU2019284080A patent/AU2019284080B2/en active Active
-
2020
- 2020-06-05 US US16/893,972 patent/US11679128B2/en active Active
-
2021
- 2021-04-28 AU AU2021202640A patent/AU2021202640B2/en active Active
-
2022
- 2022-01-28 JP JP2022011975A patent/JP7252383B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102131828A (zh) * | 2007-06-18 | 2011-07-20 | 奥根农股份公司 | 针对人程序性死亡受体pd-1的抗体 |
| CN102119214A (zh) * | 2008-07-18 | 2011-07-06 | 森托科隆国际公司 | 适合于癌症治疗的包含体外扩增的t淋巴细胞和血管形成抑制剂的组合物 |
| CN102935228A (zh) * | 2011-08-15 | 2013-02-20 | 傅阳心 | 用于肿瘤治疗的试剂、其用途及方法 |
Non-Patent Citations (1)
| Title |
|---|
| Selection of CD8+ PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T-cells;Takashi Inozume et al.;《J Immunother.》;第33卷(第9期);摘要，第956页右栏倒数第1段，第957页左栏第1段，右栏倒数第1段，第958页右栏第1段，第962页左栏倒数第1段，图1，图2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021202640A1 (en) | 2021-05-27 |
| CN105163745A (zh) | 2015-12-16 |
| CA2902448A1 (en) | 2014-09-04 |
| JP2018082702A (ja) | 2018-05-31 |
| US20180133253A1 (en) | 2018-05-17 |
| JP6257655B2 (ja) | 2018-01-10 |
| JP6903558B2 (ja) | 2021-07-14 |
| JP7252383B2 (ja) | 2023-04-04 |
| AU2018204458B2 (en) | 2019-09-26 |
| EP2961416B1 (en) | 2019-11-13 |
| CN105163745B (zh) | 2020-06-12 |
| AU2019284080B2 (en) | 2021-02-11 |
| AU2019284080A1 (en) | 2020-01-23 |
| US11679128B2 (en) | 2023-06-20 |
| AU2013379773A1 (en) | 2015-09-17 |
| JP2022058791A (ja) | 2022-04-12 |
| JP2020054371A (ja) | 2020-04-09 |
| AU2021202640B2 (en) | 2023-04-13 |
| CA2902448C (en) | 2023-04-18 |
| US9844569B2 (en) | 2017-12-19 |
| WO2014133568A1 (en) | 2014-09-04 |
| AU2018204458A1 (en) | 2018-07-12 |
| AU2013379773B2 (en) | 2018-04-19 |
| US10716809B2 (en) | 2020-07-21 |
| US20160008400A1 (en) | 2016-01-14 |
| JP7029617B2 (ja) | 2022-03-04 |
| EP3628322A1 (en) | 2020-04-01 |
| US20200323908A1 (en) | 2020-10-15 |
| EP2961416A1 (en) | 2016-01-06 |
| CN111643524A (zh) | 2020-09-11 |
| ES2771251T3 (es) | 2020-07-06 |
| JP2016509840A (ja) | 2016-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111643524B (zh) | 从外周血中产生肿瘤反应性t细胞富集群的方法 | |
| JP7181917B2 (ja) | 濃縮された腫瘍反応性ｔ細胞集団を腫瘍から作製する方法 | |
| HK40035292A (en) | Methods of producing enriched populations of tumor reactive t cells from peripheral blood | |
| RU2808817C2 (ru) | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток | |
| HK40026892A (en) | Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer | |
| HK40035292B (zh) | 从外周血中产生肿瘤反应性t细胞富集群的方法 | |
| HK40053468A (en) | Methods of producing enriched populations of tumor-reactive t cells from tumor | |
| KR20240170059A (ko) | 면역 세포 치료를 위한 종양 반응성이 있는 t 세포 집단을 활성화시켜 증식하는 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40035292 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |